Antidepressant Hearings Offer Starting Point For Vioxx Investigation
Executive Summary
The congressional interest in pediatric antidepressant safety data will provide a springboard for investigations into the withdrawal of Merck's COX-2 inhibitor Vioxx
You may also be interested in...
Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
Vioxx, Drug Safety Issues Top Health Committee Agenda – If Gregg Stays
The Senate Health Committee plans to look into FDA's handling of Vioxx, antidepressant safety and flu vaccine, committee counsel Steve Irizarry said at the Healthcare Distribution Management Association annual meeting in Palm Desert, Calif. Nov. 4